Mylan Specialty

Company snapshot

Mylan Specialty, a subsidiary of Mylan Inc. (NASDAQ: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, severe allergic reactions and psychiatric disorders. The company puts patients first and facilitates efficient, cost-effective partnerships with customers.

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Mylan Specialty. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Mylan Specialty.

1. Jun 8, 2026 Clinical update

   MYL-1603N-3001 — Phase 3

2. Jun 8, 2026 Clinical update

   MYL-1603N-3002 — Phase 3

3. Jun 8, 2026 Clinical update

   EPIN-IJS-1002 — Phase 1

4. Jun 5, 2026 Clinical update

   MR-130A-01 — Phase 2

View all clinical trial activity →

• What is Mylan Specialty?

  Mylan Pharma UK is a pharma organization headquartered in CN. Primary therapeutic focus areas include Major Depression Disorder, Major Depression Disorders. NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA,

• Is Mylan Specialty publicly traded?

  Mylan Specialty appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Mylan Specialty develop or market?

  We link 10 drug profile(s) where Mylan Specialty is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/mylan-dura-gmbh#company-drugs.

• What are the latest developments for Mylan Specialty?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Mylan Specialty focus on?

  Mylan Specialty focuses on Major Depression Disorder, Major Depression Disorders based on our analysis of their pipeline programs and drug development activities.